Log In
BCIQ
Print this Print this
 

Inavir, laninamivir octanoate (CS-8958)

Also known as: CS8958

  Manage Alerts
Collapse Summary General Information
Company Daiichi Sankyo Co. Ltd.
DescriptionSecond-generation long-acting neuraminidase inhibitor (LANI)
Molecular Target Neuraminidase
Mechanism of ActionNeuraminidase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationInfluenza virus
Indication DetailsPrevent influenza A and B infection in people over 10 years of age; Prevent transmission of influenza A and B infection to other family members of a patient with confirmed influenza infection; Treat influenza A and B in adults and children; Treat influenza in geriatric patients; Treat influenza infection; Treat influenza type A or B virus infection in pediatric patients
Regulatory Designation Japan - Standard Review (Prevent transmission of influenza A and B infection to other family members of a patient with confirmed influenza infection)
PartnerAviragen Therapeutics Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$20.0M

$20.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/25/2016

$20.0M

$20.0M

0

Get a free BioCentury trial today